Dendreon and Cell Therapeutics Sell Stock, Microsoft Buys BigPark, Calistoga Raises $30M, & More Seattle-Area Deals News

5/12/09Follow @gthuang

(Page 2 of 2)

around $550,000, according to media reports. Foodista, which was founded by two ex-Amazon veterans, launched its wiki site in December.

—Neelan Choksi of Lexcycle, the e-book software startup recently bought by Amazon, gave me the scoop on his experiences as an MIT blackjack team member and dot-com entrepreneur, the story of Lexcycle, and his thoughts on moving to Seattle. Lexcycle is the maker of Stanza, a popular iPhone application for browsing, buying, and reading e-books.

—Luke reported on the second-biggest life sciences financing of the year, Kirkland, WA-based Calistoga Pharmaceuticals’ $30 million Series B round, led by existing investors Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, and Amgen Ventures. Calistoga was founded in 2006 and is working on novel drugs for cancer and inflammation.

—Seattle-based Powerit Solutions, makers of energy efficiency and energy management technology for commercial and industrial facilities, raised $6 million from new investors Siemens Venture Capital and ArcelorMittal’s Clean Technology Fund. The round also included existing investors @Ventures and Expansion Capital Partners. Powerit will use the money to accelerate market growth and expand its product development and sales.

—Ryan reported on Seattle-based Gist’s $6.75 million Series A round, led by Foundry Group and Vulcan Capital. Gist founder T.A. McCann told me the story of how the deal originally came about through a meeting with Foundry Group’s Brad Feld in Colorado. Gist makes software to help people organize communications with business contacts and Web information about them.

Gregory T. Huang is Xconomy's Deputy Editor, National IT Editor, and the Editor of Xconomy Boston. You can e-mail him at gthuang@xconomy.com or call him at 617-252-7323. Follow @gthuang

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.